Search

Your search keyword '"Wing Fei Wong"' showing total 7 results
Start Over Author "Wing Fei Wong" Publisher elsevier bv
7 results on '"Wing Fei Wong"'

2. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients

Author

Jesus Miguens Blanco, Jonathan Hurtado, Benjamin H. Mullish, Grace F. Barker, Julian Marchesi, Isabel Garcia-Perez, Madeline Carrellas, Julie A. K. McDonald, Alexandros Pechlivanis, Jessica R. Allegretti, Zain Kassam, Austin Chiang, Michael Silverstein, Christopher C. Thompson, Kevin Kennedy, Ylaine Gerardin, Wing Fei Wong, Medical Research Council, Medical Research Council (MRC), and Imperial College Healthcare NHS Trust- BRC Funding

Subjects
medicine.medical_specialty, medicine.drug_class, Capsules, Pilot Projects, Placebo, GUT MICROBIOME, Gastroenterology, Feces, Mice, Bile Acids, 03 medical and health sciences, 0302 clinical medicine, INTESTINAL MICROBIOTA, Diabetes mellitus, Internal medicine, medicine, Animals, Humans, Microbe, Obesity, STRATEGY, Science & Technology, Gastroenterology & Hepatology, Bacteria, Hepatology, Bile acid, INSULIN SENSITIVITY, Maintenance dose, business.industry, Area under the curve, 1103 Clinical Sciences, Fecal Microbiota Transplantation, Overweight, medicine.disease, Glucagon-like peptide-1, Gastrointestinal Microbiome, Treatment, Treatment Outcome, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Metabolic syndrome, business, Life Sciences & Biomedicine, Body mass index
Abstract

Background & Aims Studies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. We performed a randomized, placebo-controlled pilot study of the effects of fecal microbiota transplantation (FMT) in obese, metabolically uncompromised patients. Methods We performed a double-blind study of 22 obese patients (body mass index [BMI] ≥ 35kg/m2) without a diagnosis of diabetes, non-alcoholic steatohepatitis, or metabolic syndrome. Participants were randomly assigned (1:1) to groups that received FMT by capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were derived from a single, lean donor (BMI, 17.5 kg/m2). Patients were followed through week 26; the primary outcome was safety. Stool and serum samples were collected from patients at baseline and at weeks 1, 4, 6, 8 and 12 after administration of the first dose of FMT or placebo and analyzed by 16S RNA gene sequencing. Stool and serum samples were analyzed for metabolomics by liquid chromatography-mass spectrometry. Additional outcomes were change in area under the curve for GLP1 at week 12. Results We observed no significant differences in adverse events between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 in either group. Patients who received FMT had sustained shifts in microbiomes associated with obesity toward those of the donor (P

Published
2020

3. 1101 – Fmt with Or Without Antibiotic Pretreatment in Patients with Ibs-D: Results of a Double-Blind, Randomized, Placebo-Controlled Trial

Author

Prashant Singh, Vivian Cheng, Zain Kassam, Shrish Budree, Wing Fei Wong, Johanna Iturrino-Moreda, Judy Nee, John M. Kelley, William Hirsch, and Anthony Lembo

Subjects
Double blind, medicine.medical_specialty, Hepatology, medicine.drug_class, business.industry, Internal medicine, Antibiotics, Gastroenterology, Placebo-controlled study, medicine, In patient, business
Published
2019

4. 7 – The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation

Author

Colleen R. Kelly, Ari Grinspan, Benjamin H. Mullish, Matthew Bohm, Zain Kassam, Madeline Carrellas, Sashi Sagi, Emmalee Phelps, Julian Marchesi, Jesus Miguens Blanco, Alexandros Pechlivanis, Monika Fischer, Jessica R. Allegretti, Julie A. K. McDonald, Wing Fei Wong, Grace F. Barker, Jonathan Hurtado, Jenna Marcus, Medical Research Council, and Medical Research Council (MRC)

Subjects
medicine.medical_specialty, Gastroenterology & Hepatology, Hepatology, business.industry, Gastroenterology, 1103 Clinical Sciences, Fecal bacteriotherapy, Clostridium difficile, medicine.disease, Inflammatory bowel disease, Internal medicine, medicine, 1114 Paediatrics and Reproductive Medicine, Icon, 1109 Neurosciences, business, computer, computer.programming_language
Published
2019

5. Tu1882 - Fecal Microbiota Transplantation Improves Gastrointestinal Graft-Versus-Host Disease and Restores the Microbiome: A Pediatric Experience

Author

Majdi Osman, Kim J Allison, Mark R. Corkins, Brandon M. Triplett, Zain Kassam, Pratik Panchal, Shrish Budree, Wing Fei Wong, Gabriela Maron, and Ronald H. Dallas

Subjects
0301 basic medicine, 03 medical and health sciences, 030104 developmental biology, Graft-versus-host disease, Hepatology, business.industry, Immunology, Gastroenterology, medicine, Fecal bacteriotherapy, Microbiome, medicine.disease, business
Published
2018

6. Tu1893 - A Double-Blind, Randomized, Placebo-Control Pilot Trial of Fecal Microbiota Transplantation Capsules from Rationally Selected Donors in Active Ulcerative Colitis

Author

Rebecca Wilcox, Peter L. Moses, Mark Smith, Peter W. Callas, Eric J. Alm, Jessica W. Crothers, Magen Phillips, Cheryl Collins, Le T. Nguyen, Karen A. Fortner, Ralph C. Budd, Brigitte Lavoie, Gary M. Mawe, Zain Kassam, Elaine Vo, Ryan J. Elliott, Mario Velez, Aaron H. Cohn, Nathaniel D. Chu, Roxana Del Rio Guerra, and Wing Fei Wong

Subjects
medicine.medical_specialty, Hepatology, business.industry, Pilot trial, Gastroenterology, Fecal bacteriotherapy, Placebo, medicine.disease, Ulcerative colitis, Double blind, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, business
Published
2018

7. Do Specific Bacteria Drive Clinical Cure in Fecal Microbiota Transplantation for Clostridium Difficile Infection?: Clinical, Microbial and Metabolomic Characterization of Universal FMT Donors

Author

Colleen R. Kelly, Majdi Osman, Zain Kassam, Monika Fischer, Shrish Budree, Wing Fei Wong, Jessica R. Allegretti, Emilee Tu, Sanjay Rao, and Mark Smith

Subjects
Hepatology, biology, Gastroenterology, Fecal bacteriotherapy, Clostridium difficile, biology.organism_classification, 030226 pharmacology & pharmacy, Microbiology, 03 medical and health sciences, 0302 clinical medicine, Metabolomics, Immunology, 030211 gastroenterology & hepatology, Bacteria
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results